UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

~~December 10~~January 28, ~~2025~~2026

Date of Report (Date of earliest event reported)

___________________________________

Elevance Health, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Indiana			001-16751			35-2145715
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification Number)


Indiana (State or other jurisdiction of incorporation or organization)			001-16751 (Commission File Number)			35-2145715 (I.R.S. Employer Identification Number)

220 Virginia Ave

Indianapolis, IN 46204

(Address of principal executive offices and zip code)

(833) 401-1577

(Registrant's telephone number, including area code)

________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, Par Value $0.01	ELV	NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 52.02 ~~Departure~~- ofResults ~~Directors or Certain Officers; Election~~ of ~~Directors;~~Operations ~~Appointment~~and ofFinancial ~~Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

On ~~December~~January 1028, ~~2025~~2026, ~~the Board of Directors (the “Board”) of~~ Elevance Health, Inc. ~~(the~~issued ~~“Company”) elected Amy W. Schulman to serve as an independent director effective January 12, 2026, with~~ a ~~term~~press ~~expiring~~release atreporting ~~the Company’s 2028 annual meeting of shareholders. The Board also appointed Ms. Schulman to~~ its ~~Audit~~fourth ~~and~~quarter ~~Finance Committees.~~ and

~~There~~full isyear no2025 ~~arrangement~~financial ~~or understanding between Ms~~results. ~~Schulman~~A ~~and~~copy ~~any other person pursuant to which she was elected to the Board, and Ms. Schulman has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a)~~ of ~~Regulation S-K of~~ the ~~Securities~~press ~~Exchange~~release ~~Act~~is offurnished ~~1934,~~ as ~~amended.~~Exhibit ~~The Board has determined that Ms~~99.1 ~~Schulman~~to ~~qualifies~~this asreport ~~an "independent director" as defined by the NYSE's listing standards~~ and ~~the~~incorporated ~~Company's~~herein ~~director independence guidelines, and as an “audit committee financial expert” as defined~~ by ~~the Securities and Exchange Commission regulations~~reference.

MsNone of the information furnished in Item 2.02 ~~Schulman~~or ~~will~~Exhibit ~~receive~~99.1 ~~compensation~~hereto shall be deemed to be “filed” for ~~her~~purposes ~~services~~of Section 18 of the Securities Exchange Act of 1934, as aamended. ~~director~~Unless expressly set forth by specific reference in ~~accordance~~such ~~with~~filings, none of the ~~Company’s~~information ~~standard~~furnished ~~compensation~~in ~~program~~this ~~for~~report ~~non-employee~~shall ~~directors,~~be ~~which~~incorporated isby ~~filed~~reference asin ~~Exhibit~~any ~~10.7~~filing tounder the ~~Company’s~~Securities ~~Quarterly~~Act ~~Report~~of on1933, ~~Form~~as ~~10-Q~~amended, ~~for~~whether made before or after the ~~quarter~~date ~~ended~~hereof ~~June~~and ~~30,~~regardless ~~2025~~of any general incorporation language in such filings.

A copy of the Company’s press release announcing Ms. Schulman's election is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No			Exhibit
Exhibit No.			Exhibit
99.1			Press Release, dated ~~December~~January 1028, ~~2025~~2026, ~~announcing~~reporting ~~the~~Elevance ~~election~~Health, ~~of Amy W~~Inc. ~~Schulman~~financial toresults for the ~~Elevance~~quarter ~~Health,~~ended ~~Inc.~~December ~~Board~~31, ~~of Directors~~2025.
104			Cover Page Interactive Data File (embedded within the Inline XBRL ~~doc~~document)

FORWARD-LOOKING STATEMENTS

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan," "potential," "predict” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement

in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this ~~10th~~28th day of ~~December~~January, ~~2025~~2026.


ELEVANCE HEALTH, INC.

By:						/s/ Kathleen S. Kiefer
Name:						Kathleen S. Kiefer
Title:						Chief Governance Officer and Corporate Secretary

Filing Compare · Elevance Health, Inc.